Amgen (AMGN) Financial Analysis & Valuation | Quarter Chart
Amgen (AMGN)
AMGNPrice: $360.55
Fair Value: 🔒
🔒score
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthriti... more
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses ... more
Description
Shares
| Market Cap | $194.59B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Bradway |
| IPO Date | 1983-06-17 | CAGR | 0.21% |
| Employees | 28,000 | Website | www.amgen.com |
| Div. Yield | 2.72% | Payout Ratio | 0.67% |
| Buy Back Yield | — | Total Yield | 2.72% |
AMGN chart loading...
Fundamentals
Technicals
| Enterprise Value | $246.75B | P/E Ratio | 16.31 |
| Forward P/E | 15.36 | PEG Ratio | 5.7 |
| P/S Ratio | 5.56 | P/B Ratio | 22.52 |
| P/CF Ratio | 19.23 | P/FCF Ratio | 24.05 |
| EPS | $22.1 | EPS Growth 1Y | 31.11% |
| EPS Growth 3Y | -2.31% | EPS Growth 5Y | 19.06% |
| Revenue Growth 1Y | 9.12% | Gross Margin | 0.71% |
| Operating Margin | 0.32% | Profit Margin | 0.21% |
| ROE | 0.89% | ROA | 0.08% |
| ROCE | 0.17% | Current Ratio | 1.26 |
| Quick Ratio | 1.01 | Cash Ratio | 0.48 |
| Debt/Equity | 6.24 | Interest Coverage | 4.36 |
| Altman Z Score | 2.37 | Piotroski Score | 8 |